Songjiang Ma Sells 2,000 Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) Stock

Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Songjiang Ma sold 2,000 shares of the company’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $12.40, for a total transaction of $24,800.00. Following the sale, the president now directly owns 2,920,467 shares of the company’s stock, valued at approximately $36,213,790.80. This represents a 0.07 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Songjiang Ma also recently made the following trade(s):

• On Monday, December 30th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $12.50, for a total value of $25,000.00.
• On Thursday, December 26th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $12.70, for a total value of $25,400.00.
• On Monday, December 23rd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $12.27, for a total value of $24,540.00.
• On Thursday, December 19th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.82, for a total transaction of $21,640.00.
• On Tuesday, December 17th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $11.05, for a total transaction of $22,100.00.

Gyre Therapeutics Stock Performance

NASDAQ GYRE opened at $9.99 on Wednesday. The stock’s 50 day simple moving average is $12.30 and its 200 day simple moving average is $12.67. Gyre Therapeutics, Inc. has a one year low of $8.26 and a one year high of $27.10.

Institutional Trading of Gyre Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in GYRE. FMR LLC acquired a new position in Gyre Therapeutics during the 3rd quarter worth about $47,000. Barclays PLC lifted its position in shares of Gyre Therapeutics by 281.8% during the third quarter. Barclays PLC now owns 9,288 shares of the company’s stock worth $116,000 after purchasing an additional 6,855 shares in the last quarter. Rhumbline Advisers bought a new stake in shares of Gyre Therapeutics during the second quarter valued at approximately $123,000. Renaissance Technologies LLC acquired a new stake in shares of Gyre Therapeutics in the second quarter valued at approximately $166,000. Finally, Bank of New York Mellon Corp bought a new position in Gyre Therapeutics in the 2nd quarter worth approximately $218,000. 23.99% of the stock is currently owned by institutional investors and hedge funds.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.